Oppenheimer Downgrades Cadence Pharmaceuticals (CADX) to Perform
More News related to CADX
- Cadence Pharma (CADX) Feb volatility at 182, May at 104 into PDUFA
- Oppenheimer Downgrades Cadence Pharmaceuticals (CADX) to Perform
- Cadence Pharma (CADX) Dec volatility at 63, Feb at 111 into FDA goal date
- FDA Extends Cadence Pharmaceuticals (CADX) PDUFA Date by Three Months
- Cadence Pharmaceuticals (CADX) Up Ahead of Tomorrow's PDUFA Date
More News related to Downgrades
- S&P Lowers Pinnacle Entertainment (PNK) Outlook from Stable to Negative
- Mindspeed (MSPD) Moving Lower as Brigantine Downgrades to Hold
- Davenport Downgrades Electronic Arts (ERTS) to Sell; Lowers Q4, 2010-11 Estimates
- Stifel Nicolaus Downgrades Parkway Properties (PKY) to Sell
- Craig-Hallum Downgrades Terremark (TMRK) to Accumulate
Oppenheimer downgrades Cadence Pharmaceuticals (Nasdaq: CADX) from Outperform to Perform.
To see more analyst ratings on CADX Click Here.
Cadence Pharmaceuticals, Inc., a biopharmaceutical company, focuses on in-licensing, developing, and commercializing proprietary product candidates principally for use in the hospital setting in the United States and Canada.
Related Categories
DowngradesStocks Mentioned
+0.45Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
